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 2 
Abstract  38 
Pregnancy is a complex and vulnerable period that presents a number of challenges to women, 39 
including the development of postpartum psychiatric disorders (PPDs). These disorders can include 40 
postpartum depression and anxiety, which are relatively common, and the rare but more severe 41 
postpartum psychosis. In addition, other PPDs can include obsessive–compulsive disorder, post-42 
traumatic stress disorder and eating disorders. The aetiology of PPDs is a complex interaction of 43 
psychological, social and biological factors, in addition to genetic and environmental factors. The 44 
goals of treating postpartum mental illness are reducing maternal symptoms and supporting 45 
maternal-child and family functioning. Women and their families should receive psychoeducation 46 
about the illness, including evidence-based discussions on risks and benefits of each treatment 47 
option. Developing effective strategies in global settings that allow the delivery of targeted therapies 48 
to women with different clinical phenotypes and severities of PPD is essential. 49 
 50 
  51 
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 [H1] Introduction 52 
Pregnancy and the first year after childbirth (which collectively can be referred to as the perinatal 53 
period) is arguably one of the most transformative times in a woman’s life. This timeframe is also a 54 
complex and vulnerable period that presents a number of challenges for women. In particular, an 55 
increased risk for onset or worsening of psychiatric illness including mood disorders, anxiety 56 
disorders and psychosis exists during the first three months postpartum. All types of psychiatric 57 
disorders can occur during the postpartum period, with many chronic disorders starting before 58 
pregnancy and persisting throughout pregnancy into the postpartum period1. In this Primer, we 59 
focus specifically on the postpartum psychiatric disorders (PPDs). Collectively, the postpartum 60 
psychiatric disorders (PPDs) can include postpartum depression, which is relatively common; 61 
common anxiety disorders such as generalized anxiety disorder (GAD; which can include anxieties 62 
about the health of the baby); post-traumatic stress disorder (PTSD; which can occur due to a 63 
traumatic childbirth experience or can reflect pre-existing symptoms due to previous traumas 64 
before conception or during pregnancy); and the rarer, but usually severe presentation of 65 
postpartum psychosis. Other PPDs include eating disorders (which can worsen or recur 66 
postpartum, particularly when the infant is undergoing weaning), and obsessive–compulsive 67 




In pregnancy, depressive and anxiety disorders are common with recent population estimates of 71 
11% for depressive disorders and 15% for anxiety disorders.2 Further, antenatal anxiety and 72 
depression are one of the greatest risk factors for postpartum psychiatric disorders (PPD).3 73 
Inadequate social support and a history of adverse life events increases the risk for PPDs in all 74 
countries and levels of society4, 5. However, this risk is increased in poorer socioeconomic 75 
populations and lower income countries, due to poverty and limited access to health care.6 76 
In recent years, awareness of the potentially serious adverse consequences in both the mother 77 
and the baby associated with untreated perinatal psychiatric illness has increased. Maternal 78 
suicide due to postpartum mood disorders (including unipolar and bipolar depressive disorders) is 79 
a leading cause of maternal mortality. 7, 8,9 In addition, perinatal mood disorders are associated with 80 
an increased risk for low birth weight and premature birth, impaired mother-infant attachment, and 81 
infant malnutrition during the first year of life10, 11.  82 
In this Primer, we focus on maternal PPDs, as they are common, morbid, and have a growing 83 
literature on the underlying pathophysiology. These disorders should not be confused with the so-84 
called ’baby blues’, which are usually described as transient mild mood and anxiety symptoms that 85 
often persist ≤2 weeks and usually resolve spontaneously with no sequelae.12 If the symptoms of 86 
the ‘baby blues’ worsen and/or persist, they are considered PPDs. Herein we discuss the 87 
epidemiology of PPDs, and their underlying mechanisms and pathophysiology. We mainly focus on 88 
maternal PPDs, although paternal disorders are mentioned in some instances (Box 1). Importantly, 89 
we review the latest evidence on diagnosis, screening and prevention as well as management of 90 
PPDs. Lastly, we hope to put in context the public health impact of these disorders on mothers, 91 
their children and families to encourage wide scale adoption of strategies that make maternal 92 
mental health a global priority13.  93 
 94 
[H1] Epidemiology  95 
 5 
Data on the incidence of postpartum depression are from studies conducted in countries across 96 
the world, and variable incidence and prevalence are reported between countries14. By 97 
comparison, studies estimating the incidence and prevalence of postpartum psychosis are 98 
primarily carried out in Europe15, and demonstrate less variability in reported incidence and 99 
prevalence16, 17. Several methodological factors have influenced these differences. 18 For example, 100 
particularly for postpartum depression, the definition of the postpartum period is variable between 101 
studies, and has been defined as up to 4 weeks, 3 months, 6 months or 12 months postpartum19. 102 
Differences in study designs, such as using different tools to define case-groups and phenotypes 103 
can lead to variability in the reported number of cases. Data sources for postpartum depression 104 
and postpartum psychosis include self-reports and interviews, in addition to some population-105 
based register data16. Moreover, the incomplete availability of longitudinal data that is needed to 106 
distinguish between first-time and recurrent psychiatric episodes might impede calculations of the 107 
true incidence and prevalence of PPDs. Consequently, a variation in reported incidence and 108 
prevalence could be explained by differences in methodologies between studies, which make 109 
direct comparisons difficult. In addition, the diverse symptoms of PPDs pose specific challenges to 110 
the estimation of prevalence and incidence of these disorders20.  111 
As the literature surrounding the epidemiology of PPDs continues to grow with well-designed 112 
studies, we will have a better understanding of if differences in the incidence and prevalence of 113 
postpartum depression and postpartum psychosis are due to local/regional and national 114 
differences, or if the differences are due to variable study designs and data sources. This 115 
knowledge will assist hypothesis generating that might provide clues for the aetiology of these 116 
disorders. 117 
 118 
[H2] Mood disorders and anxiety  119 
 6 
Postpartum depression, comprising major depressive disorder and subthreshold depression, has 120 
an estimated point prevalence of 13% in high-income countries11, and ~20% in low-income and 121 
middle-income countries, 3 months postpartum (Box 2)21. In women with a history of any eating 122 
disorder, the prevalence of postpartum depression has been estimated at 35%22. Studies of 123 
postpartum depression often rely on self-reported questionnaires, including the commonly used 124 
Edinburgh Postnatal Depression Scale (EPDS)14, 23.  125 
Although the prevalence estimates for postpartum mood disorders ranges between studies, 126 
guidelines are available that state that these disorders pose substantial public health risks and 127 
consequently, must be identified and treated24,25. Moreover, there is consensus that childbirth is a 128 
strong and potent risk factor for bipolar disorder. Indeed, the risk of underlying bipolarity in first-129 
onset depression that occurs in the postpartum period is higher than in first-onset depression that 130 
occurs outside the perinatal period. In addition, women with bipolar disorder have a high risk of 131 
postpartum episodes, including depression, anxiety, mania and psychosis 26, 27. 132 
The estimated prevalence of postpartum anxiety disorders is ~10%, with a prevalence of 6% for 133 
GAD 28. Anxiety disorders have substantial comorbidity with postpartum depression and other 134 
disorders, including postpartum PTSD, eating disorders and the exacerbation of personality 135 
disorders17.  136 
 137 
 [H2] Postpartum psychosis  138 
The onset of a severe mental disorder requiring acute inpatient psychiatric treatment in the first 139 
postpartum months is ~1 per 1,000 births29-32, and are considered some of the most severe forms 140 
of illness in psychiatry 18. These severe psychiatric disorders that have an onset in the immediate 141 
postpartum period are often called postpartum psychosis, which is an umbrella term for disorders 142 
recorded as, for example, mania, mixed episodes, psychotic depression, or psychosis not 143 
otherwise specified33  144 
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http://journals.sagepub.com/doi/abs/10.1177/0004867414564698?url_ver=Z39.88-145 
2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed& ] . Women with bipolar 146 
disorder have the highest risk for postpartum psychosis than women with other psychiatric 147 
diagnosis, as the risk for postpartum relapse in women with bipolar disorder is on average 37%18. 148 
However, variations also occur within bipolar disorder, as the risk of a severe episode (ie 149 
postpartum psychosis) is greater for women with bipolar I disorder than women with bipolar II 150 
disorder34. Additionally, the risk of symptom recurrence is particularly high for women with bipolar 151 
disorder who are not receiving medication during pregnancy18 .  152 
Relapse of psychosis can also occur in women with other psychiatric disorders, such as women 153 
with schizophrenia, although this is less common35 (~16% within the first 12 months postpartum) 154 
Yes—it has been added now. https://www.ncbi.nlm.nih.gov/pubmed/19188541] , and manifests 155 
differently from what is observed in women with bipolar disorder16.  156 
Despite the widespread use of the term postpartum psychosis, this diagnosis is not recognized in 157 
current classification systems, including both ICD-10 and DSM-5 36. However, it is clear that 158 
psychotic episodes are more prevalent during the postpartum period than in other periods in a 159 
woman’s life, and evidence clearly suggests a particular vulnerability in women with bipolar 160 
disorder 29. 161 
  162 
In women with severe postpartum psychiatric illness, maternal suicide is often a predominate 163 
concern. Although maternal suicide is a leading cause of maternal mortality7, the rates of 164 
completed suicide in postpartum women are lower than those in age-matched women without 165 
children37. Nonetheless, the prevention of maternal suicide is paramount and requires careful 166 
monitoring during the postpartum period and possibly extending beyond the first year. For 167 
example, one study demonstrated that most postpartum suicides occurred between 9 and 12 168 
 8 
months postpartum and that the perinatal suicides were by highly lethal means (such as via 169 
firearm), suggesting that limiting follow-up to 1, 3 or 6 months postpartum might be insufficient.38 170 
 171 
[H1] Mechanisms/pathophysiology  172 
As previously mentioned, childbirth is one of the most potent triggers of psychiatric illness. Given 173 
that postpartum mental health disorders are one of the few occurrences in psychiatry whereby a 174 
biological trigger occurs at a known time point, elucidating the pathophysiology of these disorders 175 
may shed light on the mechanisms of mood and psychiatric disorders more broadly, and is vital for 176 
developing new treatment approaches. 177 
The aetiology of all psychiatric disorders, including PPDs, is a complex interaction of psychological, 178 
social and biological factors, including the effect of genetic and environmental influences on risk 179 
(Figure 1)12. The involvement of particular combinations of aetiological factors differs between 180 
specific PPDs34; for example, biological factors might have a greater role in the triggering of 181 
postpartum psychosis, whereas psychosocial factors might have an important contribution in 182 
postpartum depression.34 These are areas of intense investigation and future research is needed to 183 
extend our understanding of the many ways that psychological and biological processes interface. 184 
Stopping or changing medications in women with a prior history of psychiatric disorders due to 185 
concerns about the safety of medication during pregnancy could be considered a simple 186 
explanation for the triggering of PPDs. However, continuing medication in pregnancy is protective 187 
against mood disorders in a subset of patients39. Similarly, discontinuation of medication does not 188 
guarantee that a woman will relapse40. However, there is much that is still not understood about 189 
PPDs and the onset of PPDs reflects the outcome of many different pathways that manifest in 190 
vulnerable women. Future research will need to disentangle the mechanisms of depression in 191 
women before, during and after pregnancy to increase our understanding of the similarities and 192 
differences between perinatal depression and depression occurring at other times in life. We will 193 
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next discuss current theories on psychosocial and biological contributions that increase risk for 194 
PPDs.  195 
 196 
[H2] Psychosocial factors and comorbidities  197 
Psychological and social stressors contribute to the development of maternal PPDs and are 223 
associated with poorer outcomes in the infants or children41, 42. In particular, adverse life events 224 
and a history of trauma have a greater prevalence in women that develop postpartum mood 225 
disorders, compared with mood disorders outside of the perinatal period 4, 43, 44. A history of 226 
adverse early life experiences can substantially affect a mother’s ability to have a strong 227 
attachment with her infant45, and adverse parent–infant interactions and worse attachment are 228 
associated with development of PPDs 46-48.  229 
Social support has a vital role in either contributing to or mitigating the impact of postpartum mood 230 
disorders on both the mother and child49. Indeed, social support, or the degree of tangible support 231 
provided from the social network of the mother and from the partner (such as financial support or 232 
assisting with infant care), have the greatest effects on postpartum depression 50.  233 
 234 
Other psychosocial risk factors include a past history of a mood disorder, which is consistently 235 
associated with an increased risk of postpartum depression and postpartum psychosis34. In 236 
addition, although the strength of the association between risk factors and PPDs is variable 237 
between high-income countries and low-income and middle-income countries, one of the strongest 238 
psychosocial risk factors in both settings is domestic violence and previous abuse, including abuse 239 
during childhood. 4, 51 Other risk factors with a medium to strong association with PPDs include 240 
marital difficulties, migration status and antenatal depression or anxiety17, 52. In addition, poverty, 241 
young age (between 14 and 21 years of age), substance misuse, increased parity, multiple births, 242 
an unwanted pregnancy, neuroticism, pregnancy complications including obesity and comorbidities 243 
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(for example diabetes, hypertension and pre-eclampia) and neonatal problems are associated with 244 
PPDs17. 245 
 246 
 [H2] Genetic factors 247 
Data from twin and adoption studies have implicated genetic factors in the aetiology of psychiatric 248 
disorders outside of the perinatal period, including schizophrenia and mood disorders53, 54. 249 
However, only recently have genetic investigations, primarily of postpartum depression and 250 
postpartum psychosis, been conducted. 251 
Genetic epidemiological and linkage studies for postpartum depression have demonstrated the 252 
involvement of genetic factors 55, 56, 57 and two studies have demonstrated the increased heritability 253 
of postpartum depression compared with depression outside of the perinatal period58, 59. To date, 254 
studies have suggested that episodes of postpartum psychosis are a marker for a more-familial 255 
form of bipolar disorder and that the puerperal triggering of bipolar illness is familial. 60, 61. However, 256 
a genome-wide association study (GWAS) for either postpartum depression or postpartum 257 
psychosis using modern genomics methods has not yet been carried out. Future genetic studies of 258 
postpartum mood disorders using modern genomics methods will require international 259 
collaborations and consortia to include large number of patients; these studies are currently 260 
underway62, 63.  261 
Psychological stressors and early life adverse events have a lasting negative impact and can result 262 
in pathophysiological changes and altered gene expression due to increased allostatic load (the 263 
cumulative stress on the body that is a sum of lifetime exposure to stress)64. Potential mechanisms 264 
underlying how stressful life events change gene expression include epigenetic modification (such 265 
as DNA methylation and histone modification that change DNA accessibility and chromatin 266 
structure, subsequently regulating gene expression)65, changes in transcriptional control of stress-267 
responsive pathways66, and shortened telomere length67, 68 . Epigenetic alterations have been 268 
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reported in two genes, HP1BP3 and TTC9B, which have different methylation patterns in women 269 
with postpartum depression, depending on whether the mood symptoms begin during pregnancy 270 
and continue into the postpartum period, compared with symptoms that develop postpartum only 69, 271 
70
. These data indicate that different gene patterns might arise based on the timing of symptom 272 
onset. However, given the history of non-replication in many genetic studies, these findings require 273 
replication and overall, the mechanism of action in postpartum depression remains to be 274 
established.  275 
 276 
 [H2] Sleep Disruption 277 
An almost universal feature of pregnancy and childbirth is disruption to sleep. In addition, sleep 278 
and circadian rhythm disruption can trigger the onset of psychiatric disorders, particularly episodes 279 
of mania in the postpartum period71, 72. Thus, that circadian rhythm disruption has not received 280 
more attention as a potential mechanism in PPDs is surprising. 281 
Numerous studies have demonstrated profound changes in maternal sleep patterns during the 282 
perinatal period. Pregnant women experience poorer subjective sleep quality, increased waking, 283 
and more sleep-wake transitions than women who are not pregnant73. In the postpartum period, 284 
new mothers have frequent night waking, decreased night-time sleep, increased daytime napping, 285 
and a more irregular sleep-wake schedule, which is speculated to increase the risk of PPDs74. The 286 
mechanisms underlying the reported disrupted maternal sleep patterns in the perinatal period have 287 
been reported in two cross-sectional studies. The first study demonstrated a blunted melatonin 288 
amplitude is in postpartum women, compared with non-pregnant women,75 and the second study 289 
demonstrated differences in circadian rhythms between perinatal women with depression and 290 
perinatal women without depression; indeed, in the second study, women with depression had 291 
clinically-significant circadian rhythm phase shifts.74 Further research is needed to better 292 
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understand the mechanisms of sleep disruption that might trigger PPDs and potential interventions 293 
that target the circadian rhythm disruptions during the perinatal period76.  294 
 295 
[H2] Reproductive Hormones 296 
One important hypothesis for the aetiology of PPDs is based on the temporal onset of these 297 
disorders immediately after childbirth, which is a time of major physiological change for women, 298 
including alterations in hormonal systems. Multiple lines of evidence have demonstrated that 299 
fluctuations in reproductive hormones (such as oestrogen and progesterone) during the perinatal 300 
period are substantial contributors to the development of postpartum mood disorders in vulnerable 301 
women. Gonadal steroid hormones (such as oestrogen and progesterone) are produced at very 302 
high levels during pregnancy, but rapidly decrease to pre-pregnancy levels after childbirth. One 303 
study simulated this pattern of hormone expression and demonstrated substantial mood symptoms 304 
(such as sadness, anhedonia and anxiety) during the withdrawal period in five of eight women with 305 
a history of postpartum depression, but in none of the eight women with no history of postpartum 306 
depression77. Thus, women who are vulnerable to postpartum psychiatric episodes might not have 307 
gross abnormalities in endocrine physiology (such as no differences in the absolute levels of 308 
hormones), but might have an abnormal response to the hormonal fluctuations of pregnancy and 309 
childbirth.  310 
Reproductive hormones have important functions in the central nervous system. Oestrogen and 311 
progesterone receptors are expressed throughout the brain and can modulate neurotransmission 312 
and neuroplasticity via both genomic and non-genomic mechanisms. For example, rodent studies 313 
have shown that ovariectomy reduces and estradiol administration increases brain-derived 314 
neurotrophic factor (BDNF) levels in the hippocampus and the forebrain78; BDNF levels are 315 
decreased by stress and depressive symptoms and are increased following treatment with 316 
antidepressants79. The rapid fall in oestrogen levels in the postpartum period might, therefore, 317 
 13 
reduce BDNF levels and increase susceptibility to PPDs in women who are vulnerable. Similarly, 318 
progesterone has an important role in regulating neurotransmitter synthesis, release and transport 319 
80
 and, has been shown to up-regulate BDNF expression in the hippocampus and cerebral cortex 320 
in rodent models81.  321 
The neurosteroid, allopregnanolone, which is a major metabolite of progesterone, might also have 322 
an important role in the aetiology and, potentially, in the treatment of postpartum depression82, 83. 323 
Allopregnolone is a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors84, 324 
85
 and animal models have demonstrated that intravenous allopregnolone administration 325 
significantly reduces anxiety and depressive symptoms86. Allopregnanolone concentrations reach 326 
peak physiological levels during the third trimester of pregnancy and rapidly decrease following 327 
childbirth87, 88. The failure of GABAA receptors to adapt to the rapid fluctuations in allopregnanolone 328 
levels at childbirth is hypothesized to be a trigger for postpartum depression89, 90. This line of inquiry 329 
is being further explored by the development of brexanolone (a proprietary formulation of 330 
allopregnanolone) as a treatment for postpartum depression91,92.  331 
Oxytocin is a neuroactive hormone that supports childbirth, lactation, maternal behavior, and social 332 
bonding93. Some studies have demonstrated an inverse association between circulating oxytocin 333 
levels and postpartum depression94 although other studies have not found this95 .The alterations in 334 
the oxytocin system that occur during pregnancy and childbirth do not occur in isolation, and the 335 
role of oxytocin in postpartum depression is likely to be complex and not accounted for by absolute 336 
levels, similar to the roles of other neuroactive hormones 83. 337 
Further, recent neuroimaging data increases our understanding of the neurobiological basis 338 
underlying perinatal mood disorders and the development of maternal behavior. Indeed, one study 339 
demonstrated that the effects of a polymorphism in BDNF (BDNF Val66Met) on hippocampal 340 
function are selectively modulated by estradiol96. This work lends further data to the importance of 341 
the role of sex steroids on the regulation of behavioural functions associated with psychiatric 342 
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disorders, such as emotional processing, arousal, cognition, and motivation. Thus, it follows the 343 
involvement of sex steroids of brain function could be revealed using neuroimaging. Indeed, 344 
multiple cortical and subcortical brain regions have altered activity observed using functional MRI 345 
or PET (such as, measurement of brain MAO-A97) in mothers with depression, in response to infant 346 
and non-infant emotional cues98, 99. These alterations might impact important neuronal networks 347 
that are associated with learned reward, reaction to stimuli, stress, motivation and executive 348 
functioning. In addition, recent research from functional MRI studies shows distinct neurobiological 349 
patterns that distinguish anxiety and depression occurring in the perinatal period, compared with 350 
other times of a woman’s life, and these patterns may have significant impact on the mother-infant 351 
relationship100.  352 
 353 
[H2] Other factors  354 
[H3] Stress axis. The postpartum period is a time of great flux for the HPA stress axis101. Indeed, 355 
alterations in the hypothalamic–pituitary–adrenal (HPA) axis occur during pregnancy, such as 356 
corticotropin-releasing hormone (CRH) production by the placenta, resulting in significantly 357 
increased levels during pregnancy, which abruptly decline postpartum102, and rising levels of 358 
gonadal steroids that contribute to puerperal hypertrophy of the pituitary and adrenal glands, 359 
leading to increases in ACTH and cortisol levels103. CRH fluctuations during the perinatal period 360 
might trigger HPA axis dysregulation and contribute to the onset of depressive and anxiety 361 
symptoms in a subset of vulnerable women 104; however, inconsistent findings have been 362 
reported105, 106.  363 
 364 
[H3] Thyroid hormones. Thyroid hormones have been implicated in the development of 365 
postpartum mood disorders. Thyroid binding globulin (TBG, which transports thyroid hormones in 366 
the blood) concentrations increase during pregnancy and might be an index of sensitivity to 367 
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elevated oestrogen levels. Some data also suggest that decreased [Au:OK? YES] TBG levels are 368 
a predictor of perinatal depression107. In addition, first-onset postpartum autoimmune thyroid 369 
disorders often co-occur with postpartum mood disorders 108. The occurrence of both disorders 370 
coincides with the postpartum rebound phenomena of the maternal immune system, suggesting an 371 
overlap in aetiology109. Supporting this hypothesis, women with increased thyroid peroxidase 372 
antibodies during pregnancy have an increased risk for postpartum psychiatric episodes109, 110. 373 
Accordingly, the assessment of thyroid function (such as measurement of thyroid-stimulating 374 
hormone levels, tri-iodothyronine (T3) and tetraiodothyronine (T4)) is an essential part of diagnostic 375 
evaluations in women with postpartum psychiatric episodes.  376 
 377 
[H3] Neuroimmune pathways. Neuroimmune pathways might also have a role in the 378 
pathophysiology of postpartum mood disorders101, 111-113. The transition from pregnancy into the 379 
postpartum period is characterized by an accelerated immune response (mediated through both 380 
pro-inflammatory and anti-inflammatory mediators for healing and involution) during labor that 381 
continues into the early postpartum period 114. Consequently, immune changes at the end of 382 
pregnancy might predict postpartum depression. IL-6 levels are increased in women with 383 
postpartum depression compared with postpartum women who do not have depression in some, 384 
but not all studies. 112,115 However, leptin (a protein hormone made by adipose cells that regulates 385 
energy and has inflammatory functions might also be associated with postpartum depression. 386 
Indeed, decreased maternal serum leptin levels during delivery are associated with a higher risk for 387 
postpartum depression, and might potentially serve as a biomarker for postpartum depression115. 388 
Lower levels of Clara cell protein (CC16, an endogenous anti-inflammatory compound) are 389 
associated with PPD a few weeks later116, 117. Furthermore, decreased levels of ω3 390 
polyunsaturated fatty acids (PUFAs) at the end of the third trimester are suggested to associate 391 
with increased risk of PPD in the early postpartum period118. The underlying mechanism is 392 
hypothesized to be increased peripheral inflammation118 owing to the anti-inflammatory effects of 393 
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ω3 PUFAs. In summary, dysregulation of the crosstalk between the immune system and the HPA-394 
stress axis is hypothesized to be associated with the onset of postpartum depression101, 119  395 
Interestingly, first pregnancies are more often followed by psychiatric episodes than subsequent 396 
pregnancies, which may illustrate the dysregulation of psychoneuroimmune systems. This effect is 397 
hypothesized to be due to the biological differences between first and subsequent pregnancies, 398 
and has raised the possibility of an aetiological link with other medical conditions that have a 399 
similar increase in prevalence in first pregnancies such as pre-eclampsia120. Intriguingly, pre-400 
eclampsia and postpartum psychosis are both associated with immune dysregulation, for example 401 
the increased rates of postpartum autoimmune thyroiditis108, 109 and alterations in immune 402 
biomarkers (such as, CNS autoantibodies) in women with postpartum psychosis121. In addition, 403 
abnormalities in monocyte and T cell function and tryptophan breakdown has been demonstrated 404 
in patients with postpartum psychosis or mania, compared with postpartum women without any 405 
psychiatric symptoms.122 Patients with postpartum psychosis had monocytosis and failed to 406 
demonstrate the physiological T- cell increase that is normally observed during the postpartum 407 
period. These findings support the notion that immune system dysregulation contributes to 408 
affective instability and severe postpartum episodes122.  409 
Future studies are needed to extend our understanding of the ways in which psychological and 410 
biological processes interact in PPDs. For example, social support might exert a stress-buffering 411 
effect via the downregulation of stress responses, including inflammatory reactivity to stressors and 412 
dampened sympathetic and hypothalamic-pituitary-adrenal (HPA) axis activity 123, 124.  413 
[H1] Diagnosis, Screening and Prevention  414 
As with all psychiatric disorders, the diagnosis of postpartum depression is reached by a 415 
comprehensive clinical interview and diagnostic criteria that provide an operationalised definition of 416 
the disorder, using classification systems such as the Diagnostic and Statistical Manual of Mental 417 
Disorders, Fifth Edition (DSM-5)125 or International Classification of Diseases, Tenth Edition 418 
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(ICD10)126. Diagnostic criteria are similar across the DSM-5 and ICD-10, which are the two most 419 
common classification systems; however, the DSM-5 uses the term ‘depression with peripartum 420 
onset’ to refer to the onset of depression during pregnancy and into the first month postpartum, 421 
whereas ICD10 does not use a primary code referring to the perinatal period, although a second 422 
code denoting postpartum onset is available (which is not used in practice) . However, the 423 
diagnosis of psychiatric disorders is more than a list of symptoms and the impact on symptoms of 424 
functioning; diagnosis should also include an understanding of predisposing aetiological factors, 425 
triggers and maintenance factors, which are elicited by a comprehensive biopsychosocial 426 
assessment24. 427 
Postpartum depression is one of the most common postpartum psychiatric disorders, and can be 428 
mild and relatively self-limiting lasting only a few weeks, or can be more severe, with severe 429 
episodes potentially including psychotic symptoms17. Some symptoms of depression such as 430 
fatigue, sleep disturbance and appetite disturbance need careful enquiry, as a woman with a baby 431 
will be more tired than usual and have disrupted sleep (due to the baby needing a feed), although 432 
appetite might not be affected as breastfeeding will stimulate appetite despite a low mood. 433 
Checking whether the mother is able to sleep when the baby is asleep, whether the fatigue persists 434 
after rest and the interest in food will help establish whether the symptoms are pathological and if 435 
they are indicative of postpartum depression. Notably, anxiety might be a prominent symptom in 436 
postpartum depression63, or can be a symptom of a comorbid anxiety disorder127. Diagnostic 437 
assessment should evaluate a history of manic or hypomanic symptoms, as first-onset postpartum 438 
depression can indicate underlying bipolar disorder26. Diagnostic challenges include barriers to 439 
disclosing symptoms due to stigma128 and variations in the manifestation of symptoms, which might 440 
reflect cultural or educational differences129. In addition, it is important to ensure symptoms are not 441 
due to an underlying medical condition such as thyroid disease or an early presentation of first 442 
episode psychosis.  443 
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Although postpartum psychosis is not included as a primary diagnosis in the DSM-5 or ICD-10, this 444 
disorder is still recognised clinically and is usually considered to be a severe mood disorder.16 445 
Women with postpartum psychosis often have a history of bipolar disorder.16 Most women have 446 
prodromal symptoms before the overt onset of postpartum psychosis; however, some women have 447 
acute onset of severe symptoms 130, 131. Evaluation of women with postpartum psychosis includes 448 
assessment of manic, depressed, anxious and psychotic symptoms, and the assessment of the 449 
risk of causing harm to herself or her baby. Women with postpartum psychosis can present with 450 
either low or high mood (both elation and irritability), or frequently can present with a mixed state, 451 
including symptoms of both mania and ; a minority of women have an atypical symptom profile with 452 
disorientation and/or disturbance of consciousness 132. Symptoms can also manifest as delusions, 453 
hallucinations, and particularly confusion and perplexity and patients can also have severe mood 454 
swings, insomnia, agitation and rapid deterioration. Postpartum psychosis is usually a rapid onset 455 
severe psychosis, typically starting within the first 2-4 weeks after birth, and is considered a 456 
psychiatric emergency as a lack of self-care and an inability to care for the infant can lead to 457 
suicide and/or, in rare cases, infanticide16. Accordingly, assessment should be carried out quickly 458 
(for example, The National Institute for Health and Care Excellence (NICE) recommend 459 
assessment within 4 hours of clinical presentation; in clinical practice this means within 24 hours of 460 
the acute onset of severe psychiatric symptoms) to ensure the woman can be cared for safely and 461 
appropriately. Excluding other medical disorders, such as cerebral space occupying lesions, 462 
thyroid disorders or infections is important as part of the diagnostic work-up. In many cases the 463 
mother’s partner or family ask for psychiatric evaluation when the mother is irritated or agitated and 464 
not aware that she is seriously ill. 465 
 466 
Anxiety disorders (such as GAD and panic disorder), OCD and PTSD can all manifest in the 467 
postpartum period. OCD is characterised obsessive thoughts. Obsessions are intrusive, repetitive 468 
thoughts, images or impulses that are unacceptable and/or unwanted and give rise to subjective 469 
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resistance. By contrast, delusions that occur in psychotic disorders are fixed, false beliefs133 that 470 
need appropriate psychological intervention17. Postpartum OCD poses a particular diagnostic 471 
challenge, as intrusive thoughts about harm befalling the infant (such as, what if I drop my infant or 472 
I accidently cut the infant with a knife when I’m cooking) might be perceived as delusional and 473 
could lead to concerns about the safety of the infant. However, these thoughts are not associated 474 
with actual direct harm and the obsessions remain very ego-dystonic and highly distressing to the 475 
patient. Traumatic childbirth experiences can trigger PTSD, particularly in women with prior 476 
histories of trauma134. Differentiating the exacerbation of PTSD symptoms in women with past 477 
trauma and new onset PTSD owing to traumatic childbirth is important135. Past trauma history 478 
should include assessment of prior childhood abuse, adult interpersonal or other violence, among 479 
other forms of trauma. In addition, many women with PTSD or OCD present with symptoms of 480 
anxiety and mood symptoms, making the diagnosis of any one particular disorder a challenge63, 136.  481 
 482 
Women with a previous history of psychiatric disorders will often experience a worsening of 483 
symptoms during the postpartum period, although few studies have examined strategies to 484 
mitigate this exacerbation of symptoms39. For women without a prior history of psychiatric 485 
disorders, the acute onset of psychiatric symptoms in the postpartum period is often highly 486 
distressing. However, whether the first onset of psychiatric symptoms in the postpartum period 487 
indicates the beginning of a more persistent and chronic mood disorder, or is a condition that will 488 
be restricted only to the postpartum period is unclear. This is an important area for future study.  489 
 490 
[H2] Screening  491 
Screening for postpartum depression has attracted widespread interest from researchers, clinicians 492 
and policy makers due to the high prevalence and associated sequelae in terms of maternal 493 
morbidity and adverse child outcomes. In many countries, screening for postpartum depression 494 
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during routine obstetrical care, including care by health visitors, is inconsistent, and this strategy 495 
has become an area of focus in many countries. In addition, up to 60% of perinatal women with 496 
depression do not seek help 137. However, given the availability of screening instruments and 497 
effective treatments 138, Clinical Practice Guidelines and recommendations are increasingly 498 
supportive of routine screening139, 140. More generally, international guidelines reflect a consensus 499 
that improved identification of PPDs is vitally important 141,142. Accordingly, several national 500 
campaign to increase awareness of PPDs are underway, such as the Maternal Mental Health 501 
Alliance143 in the UK. This alliance is a coalition of organizations that are dedicated to achieving 502 
consistent, accessible and quality mental health care in the first year after giving birth. In addition, 503 
state mandates for perinatal depression screening are increasing in the United States, including 504 
the US Preventive Services Task Force recommendation140. However, although this task force has 505 
concluded that the evidence base that is sufficient to recommend screening for perinatal 506 
depression when combined with adequate support systems25, 140 this conclusion has also been 507 
criticised by others144.  508 
The most widely researched and used screening tool for postpartum depression is the brief 10-item 509 
Edinburgh Postnatal Depression Scale (EPDS145), which was designed to exclude symptoms that 510 
can be normal features of the perinatal period, such as poor sleep, but that are often included in 511 
other self-report measures. A cut-off score of 13 is most commonly used to recommend further 512 
diagnostic assessment146, 147. In addition, the EPDS includes question about thoughts of self-harm, 513 
which can help to mobilise risk assessment and can predict suicidal intent148. The EPDS has been 514 
used prenatally and validated in a number of languages, its properties are relatively well-515 
understood 147 and it appears to be highly acceptable in the target population 149,150. High EPDS 516 
scores can reflect several psychiatric diagnoses. For example, among the 826 screen-positive 517 
women out of a sample of 10,000 women, the most common primary diagnosis was unipolar 518 
depressive disorder (found in 68.5% of women), but almost two-thirds of women had co-morbid 519 
anxiety disorder and 22.6% had a bipolar disorder 151. These data highlight another potential 520 
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benefit of the EPDS: that most women with a false-negative result for unipolar depression have 521 
another diagnosable, and potentially treatable, psychiatric condition. 522 
Other generic or perinatal-specific depression measures have been used to identify perinatal 523 
depression, but are not as well validated in perinatal women as the EPDS. Other measures include 524 
the Postpartum Depression Screening Scale152, the Beck Depression Inventory-II153 and the 525 
Patient Health Questionnaire-9154,155. Alternatively, two case finding questions (the so-called 526 
Whooley questions 141, 156, 157) can be asked to women to determine whether further mental health 527 
assessment should be carried out, and the use of these questions is recommended by NICE 528 
guidelines in the United Kingdom. The Whooley questions can also be used to detect any 529 
psychiatric disorder, and are not limited to depression2. 530 
As previously mentioned, postpartum depression are frequently co-morbid with anxiety (in 4.3% of 531 




, this has spurred efforts to screen for postpartum anxiety. Three sub-items of the EPDS (the 533 
so-called EPDS-3A) can be used to identify perinatal anxiety disorders and sub-syndromal 534 
anxiety160. Other screening instruments for anxiety disorders include the Perinatal Anxiety 535 
Screening Scale (PASS)161 and the generalized anxiety disorder scale (GAD-7)162. Screening tools 536 
for perinatal OCD and PTSD are also available, such as the specific perinatal OCD screening scale 537 
(The POCS),163 and a short screening scale for PTSD (SPAN), respectively.164.  538 
The utility of routine screening for postpartum psychosis, hypomanic and manic symptoms and 539 
bipolar disorder faces several barriers including a lack of evidence base of effectiveness and the 540 
reduced predictive value of screening for a relatively rare condition. Despite steady progress in this 541 
area165, 166 a consensus test with well-known precision and an agreed cut-off has not been 542 
identified167,168. However, the Mood Disorder Questionnaire (MDQ) has shown solid psychometric 543 
properties for assessing bipolar disorder and is increasingly used 169. Taking a full personal and 544 
family history might help to identify vulnerability to bipolar disorders which could trigger further 545 
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diagnostic assessment, given the strong association between bipolar disorder and increased risk 546 
for PPDs141, 142.  547 
In general, screening programs in the postpartum period should include a clear pathway from 548 
screening, to diagnostic assessment and treatment170. Best practice guidelines agree that all 549 
women who have a positive screen need subsequent assessment, during which, co-morbidities 550 
and the woman’s wider psychosocial context can be explored. Currently, only such well-resourced, 551 
integrated management programs have provided evidence that perinatal mental health is improved 552 
by depression screening 171, 172. In this regard, e-screening and e-treatments to facilitate integrated, 553 
cost-effective care might be useful173. Few well-understood, validated screening approaches for 554 
PPDs that can ultimately improve morbidity and mortality are available. Indeed, further building of 555 
the evidence-base for screening, including the cost-effectiveness of perinatal depression screening 556 
as a policy direction is required142, 174. 557 
 558 
[H2] Prevention  559 
Interventions for the prevention of postpartum depression or postpartum anxiety are intended to 560 
prevent the onset, duration, or recurrence of these disorders. Prevention can reduce the mental 561 
health, physical health and socio-economic burden associated with postpartum depression for 562 
mothers, their offspring and families, as well as for health systems. The effectiveness of prevention 563 
of postpartum depression is facilitated by the fact that pregnant women are motivated to address 564 
factors that will affect their baby175. The assessment of risk factors for PPDs helps with diagnosis 565 
and formulation, but is also important for identifying potentially modifiable targets for prevention 566 
and treatment (Box 3)176. Thus, it is a requirement for both symptom screening and risk 567 
assessment that systems exist for adequate follow-up and support. Furthermore, women and 568 
clinicians should be informed that the established risk factors might have limited predictive value 569 
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for individual patients and, therefore, do not guarantee which women will develop or not develop 570 
postpartum depression.  571 
Some psychosocial and psychological interventions have reduced the risk of women developing 572 
postpartum depression, although no single intervention type or modality appears superior to 573 
others. Data from trials included in a Cochrane review176 as well as randomized controlled trials 574 
included in a qualitative review,175 point towards particularly positive impacts when interventions 575 
target at-risk groups (such as women with a previous episode of depression or a recent life 576 
stressor), or include interpersonal therapy (IPT). As relationship challenges and lack of social 577 
support constitute strong risk factor for PPD, the interpersonal focus of the IPT intervention, 578 
therefore aims to address this causative or aggravating factor. Interventions with the most promise 579 
include interventions targeting at-risk groups (such as women with a previous episode of 580 
depression or a recent life stressor).  581 
Trials included in these reviews were conducted among high risk women, based on various factors, 582 
as well as women enrolled from the general perinatal population. Trials assessing the use of 583 
interpersonal therapy, cognitive behavioural therapy, peer support, parental preparedness, and 584 
person-centred approaches for prevention of postpartum depression have demonstrated 585 
significantly positive results, whereas trials assessing the use of cognitive behavioural therapy for 586 
postpartum depression have demonstrated mixed results. These results, disaggregated for 587 
universal, selective or indicated prevention strategies are summarized in a more recent systematic 588 
review and meta-analysis177. The interventions were delivered using several modalities, including 589 
home visits and telephone support, provision by professional and lay practitioners, individual and 590 
group-based sessions, through multiple contact sessions and at postpartum initiation176.  591 
There is conflicting evidence for the treatment of vulnerable women with antidepressants for the 592 
prevention of depressive episodes or anxiety symptoms during the perinatal period as well as 593 
anxiety symptoms has conflicting evidence 178. One of the earliest studies demonstrated a 594 
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reduction in recurrence of postpartum major depression with prophylactic antidepressant treatment 595 
179
. Small but emerging literature has suggested hormonal therapies, light therapy and other forms 596 
of circadian manipulation might be promising therapies for prevention of depression180. There is no 597 
strong evidence for the use of hormonal therapies, acupuncture, supplementation with omega-3 598 
polyunsaturated fatty acids, light therapy and other forms of circadian manipulation for prevention 599 
of postpartum depression. 177,180  600 
Interventions for the prevention of postpartum psychosis include careful monitoring for symptom 601 
development in women at high risk and adjustments of prophylactic medication, especially in 602 
women with bipolar disorder18, 24. Prophylactic treatment during pregnancy might reduce the rate of 603 
postpartum relapse in women with bipolar disorder, although no evidence from randomized 604 
controlled trials for this is available. For women with previous postpartum psychosis, prophylactic 605 
treatment with lithium or antipsychotics immediately postpartum might reduce relapse18.  606 
  607 
[H1] Management  608 
The goals of treating mental illness in the postpartum period are to reduce maternal psychiatric 609 
symptoms and to support maternal-child and family functioning. All women and their families 610 
should receive education about the illness and the potential treatment options, including the 611 
potential benefits and harms of each treatment option. Social support should be optimized and 612 
physical and psychiatric comorbidities should be addressed. In addition, strategies to assist women 613 
in obtaining sleep and a stable circadian rhythm are helpful, given that sleep deprivation is 614 
common during the postpartum period. In many cases, the symptoms of PPDs influence maternal–615 
child interactions, which should be observed and discussed in a non-judgmental way.  616 
Although specific recommended treatments depend on the underlying diagnosis, in general, a 617 
stepped care approach is advocated, in which the intensity of the intervention matches the severity 618 
and acuity of the clinical presentation. For example, women with mild symptoms of depressive, 619 
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anxiety, obsessive–compulsive and/or trauma or stressor-related disorders should first be offered 620 
the lowest-intensity interventions such as peer support and guided self-help, whereas women who 621 
do not respond to these treatments might require formal psychotherapeutic interventions, such as 622 
psychological therapies. For women with severe symptoms, who do not respond to non-623 
pharmacological treatment, or who have bipolar disorder or psychosis, pharmacological 624 
interventions are likely to be introduced as a first-line treatment, used alone or in combination with 625 
a lower-intensity intervention. In such cases, the well-established benefits of breastfeeding on the 626 
infant must be considered in the context of maternal mental wellbeing, the passage of psychotropic 627 
medication into breast-milk and the infant, and the potential effects of medications on the neonate. 628 
Indeed, when breast-feeding is challenging, and/or when frequent nighttime feedings leads to 629 
sleep disruption, symptoms of depression or anxiety might be precipitated or exacerbated. In these 630 
cases, the benefits of breastfeeding must be weighed against the risk of ongoing maternal mental 631 
illness, and formula feeding is a viable and often recommended alternative. Other somatic 632 
treatments, such as electroconvulsive therapy (ECT), can be considered in women with treatment-633 
refractory disorders. Throughout, monitoring progress to determine when or if to move to a higher-634 
intensity intervention, and to ensure safety for mother and child is important. In the initial 635 
assessment and during treatment the patient and her family should be asked if thoughts of suicide 636 
or infanticide have occurred. Safety concerns and/or evidence of active psychosis are medical 637 
emergencies that require specialist consultation, emergency hospitalization and treatment. 638 
 639 
[H2] Mood disorders and anxiety  640 
Treatment of postpartum depression and other non-psychotic mental disorders (such as anxiety, 641 
OCD and trauma and stressor-related disorders; Box 4) depends on the severity of the initial 642 
presentation and the level of functional impairment, including the effect on the maternal–child 643 
interaction.128 For women with a past history of mental illness, the previous treatment response and 644 
the time to response of previous episodes should be considered. The patient’s treatment 645 
 26 
preference, in addition to as access to care and utilization of care should also be considered in all 646 
women, as patients who receive their preferred treatment are most likely to benefit from this 647 
treatment than other treatments.181 Most women with non-psychotic mental disorders often prefer 648 
psychotherapy over pharmacological treatments, although the uptake and effectiveness of this 649 
therapy can be limited due to barriers in attending appointments, such as unpredictable infant 650 
schedules and competing childcare responsibilities.182 Similarly, fathers also prefer psychological 651 
treatments to pharmacological therapy.183 However, some women prefer pharmacological 652 
treatment alone, so individualizing treatments based on patient preferences is important. Treating 653 
maternal postpartum depression might not always improve the maternal–infant relationship, and 654 
additional interventions aimed at the mother–infant dyad or the family as a whole might be 655 
required.184  656 
 657 
[H3] Psychological Interventions. Most trials for postpartum depression have focused on non-658 
pharmacological treatments. For women with mild postpartum depression, psychosocial treatments 659 
including peer support, guided self-help, and supportive counseling by trained professions such as 660 
public health nurses (at home, or in support groups) can improve symptoms. For example, one 661 
systematic review of 5 trials demonstrated a 1 year remission rate of 68% in women with 662 
postpartum depression who received psychosocial treatments compared with a remission rate of 663 
54% in women treated with standard primary care.185 For women with moderate symptoms of 664 
depression, or women who do not responded to psychosocial strategies, psychotherapies such as 665 
cognitive-behaviour therapy (CBT) and interpersonal therapy (IPT) that specifically address the 666 
psychological and related challenges of transitioning to parenthood are effective when delivered in 667 
individual, group, and partner-assisted formats, and either in-person, by telephone, or online.186 A 668 
systematic review of 4 CBT and 1 IPT trials demonstrated a pooled remission rate of 60.3% for 669 
these interventions, compared with a rate of 48.1% for usual care.185  670 
 671 
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In addition, a CBT-based program was demonstrated to reduce worry and depressive symptoms in 672 
women with postpartum anxiety disorders, including GAD, social phobia and OCD, compared with 673 
symptoms at baseline.187 The effectiveness of CBT for postnatal OCD symptoms was confirmed in 674 
a small RCT.188. Although additional research is required, CBT-based interventions for postpartum 675 
anxiety disorders, and specifically interventions such as eye movement desensitization and 676 
reprocessing (EMDR) and trauma-focused CBT for trauma and stressor related disorders, can be 677 
used, although the latter two interventions have not been specifically evaluated in postpartum 678 
women [189.  679 
The increasing use of internet-based CBT and the development of mobile apps that use this 680 
treatment modality demonstrates the power of digital health, which is often more accessible than 681 
traditional psychotherapy, and extends to individuals who can’t participate in psychotherapy. A 682 
good example of this is MumMoodBooster, which was developed in Australia173.  683 
 684 
[H3] Drug therapies. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and 685 
serotonin norepinephrine reuptake inhibitors (SNRIs) are the mainstay of pharmacological 686 
treatment for postpartum anxiety and depressive disorders. These therapies can be used alone or 687 
in combination with psychosocial or psychological treatments. In a systematic review, the pooled 688 
remission rate was significantly higher in patients receiving SSRIs (46.0%) compared with those 689 
receiving placebo (25.7%).190 Although pharmacological therapies can be used alone or in 690 
combination with psychosocial or psychological treatments, whether combinatorial therapy is 691 
superior to either one alone has not been evaluated in postpartum women. However, combinatorial 692 
treatment does not lead to further improvements in functional outcomes compared with medication 693 
alone, in non-perinatal populations.191, 192 To our knowledge, there are no drug treatment trials in 694 
maternal anxiety disorders, or in paternal postpartum depression or anxiety. However, SSRI and 695 
SNRI medications are first line pharmacological treatments for anxiety and depression outside the 696 
postpartum period. The duration of antidepressant therapy required for new-onset postpartum 697 
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depression, anxiety or a related disorder has not been studied, but clinicians are recommended to 698 
follow guidelines for these disorders in the general population. For depression, the initial treatment 699 
should be continued for 6 months to 1 year after remission; longer durations are required for 700 
severe and/or recurrent illness.193 701 
  702 
Many women and their partners are concerned about the safety of using antidepressant drugs 703 
during breastfeeding. However, the use of antidepressants during the postpartum period is not a 704 
contraindication to breastfeeding, and indeed, the avoidance of medication when needed for 705 
severe illness is associated with maternal suicides194. The passage of SSRIs and SNRIs into 706 
breast-milk is variable between drugs, but most pass into the breast-milk at <10% of the maternal 707 
dose, which is compatible with breast-feeding.195 As such, changing the antidepressant drug or the 708 
dose during the perinatal period to switch to a drug with lower breast-milk passage is generally not 709 
recommended. For new-onset postpartum depression, sertraline is often recommended as a first-710 
line pharmacological treatment due to very minimal passage into breast-milk (Figure 2). However, 711 
in patients with a prior history of psychiatric disorders, therapies that have previously demonstrated 712 
efficacy should be considered, even those that have less data regarding safety during 713 
breastfeeding. Other SSRIs, SNRIs or mirtazapine (an atypical antidepressant) also have minimal 714 
passage into breast-milk, so these drugs are unlikely to be a cause for concern. Buproprion is 715 
generally not given to lactating women due to case reports of infant seizures associated with 716 
exposure to this drug.196 In cases of severe depression and/or anxiety (with or without psychotic 717 
features), older antidepressants, other therapies such as benzodiazepines or antipsychotics might 718 
be indicated.  719 
 720 
[H3] Other treatments. Given the likely role of hormonal fluctuations in the aetiology of postpartum 721 
depression, hormonal treatments have been evaluated. Transdermal oestrogen therapy reduced 722 
the symptoms of postpartum depression in one small study, but further trial are required. Progestin 723 
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therapy worsens postpartum depressive symptoms.197 One trial of demonstrated the superiority of 724 
allopregnenalone to placebo in improving depressive symptoms in 21 women with severe 725 
postpartum depression,92 although this requires further investigation. Complementary and 726 
alternative medicine treatments (for example, folate, s-adenosylmethionine, massage and 727 
acupuncture) are not well-supported by evidence.198 However, using aerobic exercise for 728 
postpartum depression was recently examined in a systematic review and has good supporting 729 
evidence for mild symptomatology 199. ECT can be considered in severe or treatment-refractory 730 
cases of depression. 731 
 732 
[H2] Postpartum psychosis  733 
Fluctuations in symptoms are common in women with postpartum psychosis, and thoughts of 734 
infanticide or suicide are often well hidden. Thus, outpatient treatment is not safe and psychiatric 735 
hospitalization is recommended for diagnostic evaluation and treatment 15. The preferred treatment 736 
setting is a mother–baby joint admission unit, but these units are not available worldwide 200, 201. 737 
Alternatives are the admission of the mother only to a hospital with expertise in perinatal 738 
psychiatric care or women’s mental health, or, if these facilities are unavailable, admission to a 739 
standard mental health inpatient setting, or based on a careful assessment of the safety of both the 740 
mother and the infant, intensive home treatment where available and with appropriate 741 
supervision16. The effect of these approaches on long term outcomes of the mother and baby are 742 
being investigated15.  743 
The management of postpartum psychosis is dependent on psychiatric history. For women with 744 
known severe psychiatric illness with non-perinatal episodes, reviewing the nature and 745 
effectiveness of past treatments and restarting previous effective treatment is important. 746 
Management of women without a history of bipolar disorder or other severe psychiatric disorder are 747 
summarized in Figure 2. The main treatment goals for women without a prior history of bipolar 748 
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disorder, psychosis or other severe psychiatric disorder include the limitation of the current episode 749 
and the prevention of a bipolar disease course with multiple episodes. Accordingly, management in 750 
the first year postpartum should focus on full recovery (that is, complete symptom remission and 751 
social and vocational functioning). In the absence of guidelines and controlled trials, treatment 752 
recommendations are based on results from naturalistic cohort studies and expert consensus 753 
groups24, 202. The largest study (consisting of 68 patients) demonstrated the efficacy of a stepwise 754 
sequence of short-term benzodiazepines, antipsychotics and lithium, and showed high remission 755 
rates (remission in 98.4% of women) in the acute phase 203. Moreover, this study demonstrated 756 
that lithium monotherapy is protective against relapse of psychosis, depression and mania within 757 
one year. The second largest study described successful ECT treatment in 34 patients with 758 
postpartum psychosis of whom many had symptoms of catatonia204. The effectiveness of lithium 759 
and ECT is supported by case reports 205. Successful treatment with antipsychotics has been 760 
described in case reports 206, 207, but antipsychotic monotherapy did not show efficacy in a cohort 761 
study 203. Together, lithium monotherapy might be the preferred initial intervention for postpartum 762 
psychosis but adjunctive treatment with benzodiazepines or antipsychotics is useful for the acute 763 
treatment of agitation, mania and psychotic symptoms, given the well documented effectiveness in 764 
non-perinatal populations. Several antipsychotics are used for the treatment of severe PPDs 765 
including risperidone, quetiapine and olanzapine208. ECT is the primary treatment for patients with 766 
severe catatonic or depressed psychotic features, or if patient’s prefer this therapy 15.  767 
Anticonvulsants (that is, antiepileptic medications) are also used less frequently as mood 768 
stabilizers in the treatment of bipolar disorder because of concerns of teratogenicity. However, 769 
valproate use during pregnancy and lactation is associated with neural tube defects and 770 
neurocognitive developmental delays in the offspring24, 209. Thus, valproate use is not advised 771 
during the perinatal period, unless the risk/benefit assessment determines a prior efficacy in 772 
particular women. By contrast, lamotrigine is used for the treatment of bipolar–depression (not 773 
bipolar–mania) and is not associated with an increased risk of congenital malformations in 774 
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offspring. 210. A review of recent studies demonstrated that lamotrigine had no adverse outcomes 775 
on infant IQ or neurodevelopment.211  776 
The management of a breastfeeding woman with a severe psychiatric episode is challenging 777 
due to concerns about the exposure of breastmilk to pharmacological therapies and the need 778 
for sleep preservation in the mother15. The use of lactation inhibitors should be avoided. In some 779 
countries, the mother is recommended to breastfeed only if extensive psychiatric support and 780 
access to a pediatric professional that can monitor the infant are available. Moreover, the mother 781 
and her partner should be educated about the risks of breastfeeding with pharmacotherapy. In 782 
other countries, a more individualized approach (for example, NICE guidelines) based on previous 783 
responses to medication, preferences regarding breastfeeding and psychopathology24, other than 784 
avoidance of breastfeeding if lithium (rather than an antipsychotic) is used. Small case series have 785 
provided information regarding the safety of lithium in lactation212, 213. When possible, level of 786 
lithium in the infants serum should be closely monitored; on average, the serum level of lithium is 787 
25% of the maternal levels, but the range can vary and dehydration can lead to toxic levels 15,213. 788 
No adverse effects were reported in ten infants of breastfeeding mothers who received ECT204. 789 
 790 
[H1] Quality of life  791 
The symptoms and morbidity of postpartum depression are often reported in the academic 792 
literature, but this offers only a rather constricted view of the quality of life (QOL) of women with 793 
PPDs. 125,214 215 Nevertheless, the classic core symptoms of a depressive disorder would be 794 
expected to decrease the subjective quality of both an individual’s inner life experience (anhedonia, 795 
sadness, hopelessness, thoughts of death), and their functioning (psychomotor retardation or 796 
agitation, disturbed sleep). Anxiety is frequently co-morbid and this further influences quality of life 797 
with persistent worry symptoms. 798 
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 Definitions vary, but QoL is a broader multidimensional construct which commonly incorporates 799 
two central aspects: emotional well-being (including, frequency and intensity of joy, sadness, 800 
affection) and life evaluation (how satisfied one is with one’s life, for example, housing, 801 
employment). Health, and the ability to function, as an essential component of QoL is referred to as 802 
health-related quality of life (HRQoL). Maternal QoL during the postpartum period also affects her 803 
infant’s current and future quality of life. Many mothers with postpartum depression have difficulty 804 
interacting with their infants in a positive way216, such as making less eye contact, showing less 805 
synchronous responsiveness, being uninvolved and showing restricted affect during mother-infant 806 
interactions.217-219 Infant attachment security is a key predictor of child outcomes, including 807 
neurological, psychological and social outcomes over the course of development220. In addition, 808 
children of mothers with perinatal depression might have poorer psychological outcomes when 809 
they reach 18 years of age221. Some women have an intrusive engagement style that might lead to 810 
long-term difficulties in child social, cognitive and behavioural domains222. Women with postpartum 811 
psychosis face even more many parenting challenges often including disrupted attachment, which 812 
impact on the quality of life for mother and child.223  813 
One of the most widely used generic measures of QOL is the 36 item short-form (SF-36)224, 225, 814 
which has eight health domains that measure limitations in physical or usual role activities due to 815 
health issues, limitations in usual role or social activities due to emotional issues, pain, mental 816 
health, vitality, and general health perceptions. The SF-36 has been used in over 1,000 817 
publications and for over 130 disorders including those that occur during the postpartum period, 818 
and both the full and short versions of this scale have been validated by numerous studies225, 226. 819 
However, few measures of QOL have been developed specifically for use in the postpartum 820 
period227 . Only 228 three instruments for use during the postpartum period were reported in one 821 
systematic review: The Mother-Generated Index (MGI)229, the Maternal Postpartum Quality of Life 822 
Questionnaire (MAPP-QOL)230 and the Rural Postpartum QOL scale (RPQoL)231. The MGI requires 823 
women to specify domains of their life that have been affected by the birth of their baby, either 824 
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positive or negative, and to then score these out of 10. 232 The most common changes reported 825 
were tiredness, less personal time, less time with partner or other family members, a worse 826 
relationship with partner or other family members, physical complaints, low self-esteem, financial 827 
worries, negative feelings towards the baby, more housework, poor sex life,  decreased pleasure 828 
from baby, less sense of happiness or fulfilment 229.  829 
Not surprisingly, people with depressive illness in general report lower scores on generic QoL and 830 
HRQoL measures, as do women experiencing postpartum depressed mood. 233 234 Small studies in 831 
postpartum women also suggest QoL is amenable to intervention. Improvements in QOL are not 832 
fully explained by improvements in the severity of depressive symptom suggesting that 833 
interventions should go beyond the mere reduction of symptom severity and consider other factors 834 
that contribute to QoL as targets for intervention. . Maternal-specific measures of QOL could be 835 
integrated into postpartum depression screening programs or routine postnatal care235, 236. Indeed, 836 
QoL measures that allow a women to identify which areas of her life are most important to her, 837 
could be used to allow women to indicate where she would like to see improvements.229 Emerging 838 
studies have highlighted the beneficial effect of social support on QOL237, in addition to risk factors 839 
for reduced QOL such as younger age and lower socio-economic status in women with postpartum 840 
depression 238. 841 
PPDs have economic considerations and can affect quality-adjusted life years (QALY)142. QALY 842 
takes into account how treatment affects quality and quantity of life, and accordingly, QoL 843 
measurement is necessary for studies of cost-effectiveness of treatments. Compelling data from 844 
the London School of Economics239 demonstrated the high economic costs of PPDs and the need 845 
to address the loss of QALYs of women and their children, by treatment and prevention of these 846 
disorders. This finding is particularly pertinent given the short and long-term effects of postpartum 847 
depression. Indeed, as most women recover from postpartum mood disorders, these disorders can 848 
become chronic in a subgroup of women240. One study demonstrated that, for each one-year 849 
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cohort of births, perinatal depression, anxiety and psychosis cost the UK around £8.1 billion in the 850 
long-term.239 851 
 852 
[H1] Outlook  853 
The postpartum period is a vulnerable time for onset of psychiatric illness. Indeed, postpartum mood 854 
and anxiety are heterogeneous and might be triggered by biopsychosocial factors including a 855 
vulnerability to the robust endocrine and immune-related changes that occur at childbirth. The 856 
heterogeneity of these disorders requires a thoughtful approach to assessment and treatment 857 
planning that includes the clinical presentation, family and personal psychiatric history, other 858 
psychosocial risk factors (including history of trauma), and awareness of potential biological or 859 
genetic contributions that might influence risk and vulnerability.  860 
The precise vulnerability that leads to some women developing PPDs is currently unknown and novel 861 
research approaches are needed to identify the underlying pathophysiology of both prepartum and 862 
postpartum anxiety, depression and psychosis. This will require a multi-faceted approach in 863 
preclinical, clinical and translational research, to determine the mechanisms behind the neurobiology 864 
and physiological correlates of PPDs, and the observed peripartum mood and mothering behaviors. 865 
Additionally, these strategies must address the differences in the timing of symptom onset and the 866 
diverse types of symptoms.  867 
Given the morbidity and mortality of postpartum psychosis, episodes of psychosis might be best 868 
considered to represent women with a bipolar disorder diathesis with a puerperal trigger. 869 
Understanding this trigger will be beneficial and should allow the development of new treatments 870 
and, ultimately, enable the prevention of psychosis or prevent unfavourable outcomes in women at 871 
high risk. Effective evidence based treatment approaches are available for psychosis and 872 
depression, including psychopharmacology, psychotherapy and ECT and circadian manipulation. 873 
However, postpartum depression and postpartum psychosis require different and targeted 874 
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treatment approaches and therefore, bipolarity must be considered in the evaluation and 875 
management of all women with postpartum mood and anxiety disorders. In addition, primary 876 
treatment goals should include the limitation of the current episode and the prevention of future 877 
episodes (including unipolar or bipolar disease with multiple episodes, and chronic anxiety). 878 
Whether there a continuum of severity between postpartum depression and postpartum psychosis, 879 
or whether these disorders represent different conditions with different aetiological factors requires 880 
further study. 881 
A potential barrier to the engagement and retention of women in the treatment of postpartum mood 882 
disorders is stigma. Understand this stigma and the fear that women have regarding postpartum 883 
mood disorders is essential. The voices of women with postpartum mood disorders must be 884 
incorporated into the development of services to ensure the needs of women, their infants and 885 
families are met241, 242.  886 
To date, the amount of research provides an important road map for PPDs in general, and 887 
guidelines for screening or identification and treatment for perinatal depression in many countries 888 
gives a strong mandate to improve mental health care for all women in the perinatal period. Thus, 889 
developing effective strategies in low, middle and high income countries that allow the delivery of 890 
targeted therapies to women with different clinical phenotypes and severity of PPDs is imperative. 891 
In addition, whether the current ICD-10 and DSM-5 classification systems are adequate for 892 
detecting specific phenotypes or diagnostic groups of patients should be evaluated. We should 893 
also consider that PPDs might be phenotypically different than psychiatric disorders that begin 894 
during pregnancy. Indeed, disorders that occur postpartum might have unique characteristics in 895 
epidemiology, pathophysiology, psychosocial contributions, prevention and management than 896 
disorders that occur during pregnancy. 897 
In summary, PPDs are morbid and costly disorders. Advocating for early identification and 898 
screening that begins in pregnancy to identify women at risk, in addition to timely and effective 899 
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treatments of PPDs is essential. Given the recent advances in knowledge, this an incredibly 900 
exciting time for research in perinatal mood disorders. New approaches might allow the 901 
identification of the underlying causes of postpartum mood disorders, which could lead efforts to 902 
identify women at risk and personalize treatment. Although genetic, biological and hormonal 903 
signals likely have an important role in risk of these disorders, psychosocial contributions including 904 
the current impact of lifetime stressors must be part of comprehensive work-up and treatment plan. 905 
The social determinants of postpartum mood disorders, such as poverty, domestic violence, poor 906 
housing, and insecure migrant status, should also be assessed as part of routine practice of 907 
maternal health care for all women. Finally, we must recognize that maternal mental health is 908 
necessary for the physical and mental health of mothers, infants and families17 and advocating and 909 
protecting this population is our obligation.  910 
 911 
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Display items 913 
 914 
Box 1. Paternal postpartum depression. 915 
Fathers can also experience depression after the birth of a child. Indeed, in men, the prevalence of 916 
depression after the birth of a child is greater than at other times during life243. Although the 917 
literature of paternal depression is much smaller than that for maternal depression, the available 918 
literature demonstrates that paternal depression increases the risk for long-term adverse outcomes 919 
in the child due to potential impairments in parenting244, 245. In addition, a strong link between 920 
maternal depression and paternal depression has been reported. Pregnant women who had 921 
partners with depression during their pregnancy had worse depression symptom severity during 922 
the first six months postpartum246. Thus, including fathers in health assessments during the 923 
postpartum period and screening fathers for postpartum psychiatric disorders at similar time 924 
intervals as maternal screening is important. Efforts aiming to improve the overall health and 925 
functioning of the family unit will lead to best outcomes for the child243, 245. 926 
 927 
 928 
  929 
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Box 2. Postpartum mental illness in low-income and middle-income countries  930 
In resource-poor settings, women of reproductive age typically have socio-economic and health 931 
challenges that interplay in mutually reinforcing ways.247, 248 For example, low levels of education, 932 
low gender status, food insecurity, domestic abuse and lack of access to social and health services 933 
leave women and girls vulnerable to maternal mortality and chronic morbidities, including common 934 
mental health disorders.249, 250 Indeed, the prevalence of common perinatal mental disorders in low- 935 
and lower-middle-income countries is higher than in high-income countries. One systematic review 936 
and meta-analysis21 demonstrated a weighted mean prevalence of 15.6% in pregnant women and 937 
19.8% in women after childbirth. The most strongly associated factors for perinatal mental 938 
disorders are socio-economic disadvantage, unintended pregnancy, younger age, unmarried 939 
status, lacking intimate partner empathy and support, hostile inlaws, partner violence, insufficient 940 
emotional and practical support, a history of mental health problems and in certain settings, a 941 
female infant. 21 942 
 943 
[H1] Considerations for management 944 
Mental health prevention and treatment investments in high-income countries is more than US$50 945 
per year per person, compared with less than US$2 in most LMIC,251 resulting in a profound 946 
paucity of mental health providers in these settings. The intervention coverage for common mental 947 
disorders (including those that occur during the perinatal period) ranges from 7% to 28% in 948 
LMICs.252 The low monetary allocation represents, in part, poor appreciation by decision makers of 949 
the effect of mental illness on population disability and socio-economic development, low levels of 950 
political will and capacity, and competing health and development priorities.253 Interventions that 951 
are most likely to succeed in LMICs would, therefore, need to adopt a systems strengthening, 952 
integrated and low-cost approach. Examples showing promise have integrated mental health into 953 
primary care, maternal and child health services or into the routine community based delivery of 954 
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health services (carried out by trained lay workers, or primary care healthworkers, using a task-955 
sharing approach)254. Emerging evidence supports the benefit of including poverty alleviation 956 
strategies in to mental health interventions.255  957 
 958 
[H1] Types of interventions 959 
A systematic review and meta-analysis of evidence of common perinatal mental disorder trials from 960 
LMIC, reported similar relative risk outcomes in studies carried out in high-income countries256. For 961 
the 13 trials selected, the pooled effect size for maternal depression was −0.38. In this review, 962 
trials that demonstrated positive results used several culturally adapted treatment paradigms, 963 
either singly or in combination. The Thinking Health Program in Pakistan was a cognitive behaviour 964 
therapy (CBT) intervention delivered in homes in a semi-rural setting by Lady Health Workers. 257 965 
Uptake of the intervention leveraged the belief, within multi-generational households, that the 966 
intervention with the mother would improve the infant’s well-being . In an urban, deprived setting in 967 
Chile, midwives and nurses were trained to deliver eight weekly structured psychoeducational 968 
group sessions. These sessions included information about symptoms and treatments, some 969 
problem solving strategies, behavioural activation strategies (such as scheduling pleasurable 970 
activities) and some cognitive techniques using postnatal examples 258 .  971 
Subsequently, a trial in Zimbabwe 259 used peer counsellors to deliver six weeks of group problem 972 
solving therapy adapted for the local setting to postnatal women with depression. In this study, 973 
family members were co-opted to support the mothers through strategies identified in the problem 974 
solving and a specific treatment element that explored community resources and support systems 975 
was included. Six weeks after the intervention, the drop in mean EPDS score was greater in the 976 
PST group than the control group who received antidepressant therapy. No difference in outcomes 977 
between women with or without HIV was reported. 978 
 979 
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Box 3. Targeting risk factors for postpartum depression. 980 
Assessing the common psychosocial risk factors for postpartum depression might have the 981 
following functions: 982 
 Assisting in the initiation of targeted interventions or determining rational management 983 
decisions to mitigate the risks across several global settings through  984 
o risk reduction interventions (for example, referring women for social grants, to 985 
domestic violence support groups or to a women’s shelter and provision of 986 
integrated interventions for the mood disorder, which also addresses domestic 987 
violence 260 988 
o activation of protective factors, (such as interpersonal therapy for relationship 989 
difficulties or activating social support networks)175, 260. 990 
 Assisting in screening of women who have an increased risk of postpartum depression but 991 
do not currently have the disorder. 992 
 Assisting in timely referral for support in women with suspected postpartum depression and 993 
complicated psychosocial risk factors who are reluctant to endorse symptoms during 994 
screening due to stigma and poor contextual validity of the screening tool in some global 995 
settings, among other reasons261. This approach acknowledges that there may be several 996 
contextual factors contributing to false negative mental health screening results. 997 
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Box 4. General management guidelines for non-psychotic psychiatric disorders  1000 
1. Identify somatic comorbidities and optimize their management.  1001 
2. Check the mode of delivery, if complications were present and if delivery was experienced 1002 
as traumatic. In the case of post-traumatic stress symptoms, consider specific treatments. 1003 
3. Assess for suicidal thoughts and intrusive thoughts of harm toward the baby. Consider the 1004 
safety of the baby and whether the mother can provide care for the baby if she is alone or if 1005 
other adult supervision is required.  1006 
4. Ask the mother of her attitude towards her baby and observe maternal-child interactions. 1007 
Consider specific treatments with signs of problematic interactions or bonding. 1008 
5. Review the feeding pattern of the baby. Address problems with breast or bottle-feeding. 1009 
6. Provide strategies to preserve sleep, such as finding another person to feed the infant at 1010 
night. 1011 
7. Assess psychiatric history before delivery. Review the nature and effectiveness of past 1012 
treatments, and restart previous effective treatment when appropriate. 1013 
 1014 
 1015 
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Figure 1, Mechanisms of postpartum psychiatric disorders.  1017 
Several factors have been implicated in the aetiology of postpartum psychiatric disorders, including 1018 
both postpartum depression and postpartum psychosis. These factors include psycho-social 1019 
factors and biological factors that are specific to pregnancy and the postpartum period, such as 1020 
drastic alterations in gonadal sex steroids and impaired mother-infant interactions. Whether the 1021 
aetiology of psychiatric disorders occurring in prenatally, during pregnancy or during the 1022 
postpartum period is different requires future study.  1023 
 1024 
Figure 2. Management of first onset postpartum psychiatric disorders. 1025 
Management of postpartum psychiatric disorders should take into account the diagnosis (such as 1026 
psychosis, anxiety or depression), symptom severity and, with regards to mood and anxiety 1027 
disorders, whether the mother is breastfeeding.  1028 
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